Bridge Biotherapeutics Risk Adjusted Performance

288330 Stock  KRW 3,455  430.00  14.21%   
Bridge Biotherapeutics risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for Bridge Biotherapeutics or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also Equity Screeners to view more equity screening tools
  
Bridge Biotherapeutics has current Risk Adjusted Performance of 0.0435.

RAP

 = 

(ER[a] - RFR) * STD[b])/STD[b]

RFR

 = 
0.0435
ER[a] = Expected return on investing in Bridge Biotherapeutics
RFR = Risk Free Rate of return. Typically T-Bill Rate
STD[b] =   Standard Deviation of selected market or benchmark.

Bridge Biotherapeutics Risk Adjusted Performance Peers Comparison

Bridge Risk Adjusted Performance Relative To Other Indicators

Bridge Biotherapeutics is number one stock in risk adjusted performance category among its peers. It is currently under evaluation in maximum drawdown category among its peers reporting about  591.96  of Maximum Drawdown per Risk Adjusted Performance. The ratio of Maximum Drawdown to Risk Adjusted Performance for Bridge Biotherapeutics is roughly  591.96 
Compare Bridge Biotherapeutics to Peers

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas